The Emergence of Biosimilars in Indonesia: Guidelines, Challenges and Prospects

Andri Wardiana, Ratih Asmana Ningrum

Abstract


According to the Food and Drug Administration (FDA), biosimilar is defined as a product which is highly similar to the reference product without clinically meaningful differences in safety, purity and potency. Indonesia is a developing country which has more than 250 million people. The domestic need of Biosmilar in Indonesia is about 10-20%.  Even though the need is very high, Indonesia still has not been able to produce Biosimilar independently. To stimulate the domestic production on biosimilar, National Agency for Drug and Food Control (NADFC) Republic of Indonesia has assigned Regulation of Biosimilar as Peraturan Kepala Badan Pengawas Obat Dan Makanan Republik Indonesia Nomor 17 Tahun 2015 Tentang Pedoman Penilaian Produk Biosimilar. The guidance covers the quality requirement and evaluation of Biosimilar products. The Ministry of Health of Indonesia has a strategic plan in biopharmaceutical covering biosimilar which is going to develop in 2015-2025. The strategy is expected to initiate biosimilar production in Indonesia. This review focuses on the guidelines, challenges and prospects biosimilars in Indonesia comparing to other international regulatory bodies.

Keywords: Biosimilar, Indonesia, Guidelines, Challenges and Prospects


Full Text:

PDF

References


Azevedo, V. F., Sandorff, E., Siemak, B., & Halbert, R. J. (2012). Potential Regulatory and Commercial Environment for Biosimilars in Latin America. Value in Health Regional Issues, 1(2), 228-234. doi:10.1016/j.vhri.2012.09.015

Behrman, R., Nardinelli, C., & Lanthier, M. (2008). Economic issues with follow-on protein products. Nature Reviews Drug Discovery, 7(9), 733-737. doi:10.1038/nrd2636

Berkowitz, S. A., Engen, J. R., Mazzeo, J. R., & Jones, G. B. (2012). Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature Reviews Drug Discovery, 11(7), 527-540. doi:10.1038/nrd3746

Bhupinder Singh Sekhon, V. S. (2011). Biosimilars: an overview. Biosimilars, 1, 1-11. doi: http://dx.doi.org/10.2147/BS.S16120

Biofarma. (2015). ProBioGenin Biosimilar bekerja sama dengan Bio Farma Indonesia Pengembangan Trastuzumab dan Pengalihan untuk Produksi Pertama di Indonesia. Retrieved from http://www.biofarma.co.id/en/uncategorized/probiogenin-biosimilar-bekerja-sama-dengan-bio-farma-indonesia-pengembangan-trastuzumab-dan-pengalihan-untuk-produksi-pertama-di-indonesia/

Biosimilars approved in Japan. (2016). Retrieved from http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan

Biosimilars Market worth $6.22 Billion by 2020. Retrieved from http://www.marketsandmarkets.com/PressReleases/global-biosimilars-product-market-worth-19.4-billion-by-2014.asp

Boehncke, W. H., & Radeke, H. H. (2007). Introduction: Definition and Classification of Biologics (pp. 1-2). Berlin, Heidelberg: Springer Berlin Heidelberg.

Chow, S.-C., & Liu, J.-p. (2009). Statistical Assessment of Biosimilar Products. Journal of Biopharmaceutical Statistics, 20(1), 10-30. doi:10.1080/10543400903280266

Direktorat jenderal Bina Kefarmasian dan alat kesehatan (2015). Renstra Industi Farmasi Indonesia dan aspek regulasi industri biosimilar. Disampaikan pada FGD Strategi dan Tantangan dalam pengembengan industri biosimilar Indonesia

FDA Approves New Insulin Glargine Basaglar – The First “Biosimilar” Insulin in the US (2016). Retrieved from https://diatribe.org/fda-approves-new-insulin-glargine-basaglar-first-biosimilar-insulin-us

FDA. (2015). ZARXIO® (filgrastim). FDA Oncologic Drugs Advisory Committee Meeting. Retrieved from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM428782.pdf

Ground Breaking Combi Dong-A Indonesia. (2016). Retrieved from http://www.combiphar.com/en/news/ground-breaking-combi-dong-indonesia

Health Canada. Summary Basis of Decision (SBD) for Omnitrope. (2009). Retrieved from http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2009_omnitrope_113380-eng.pdf

Jacob F. Siegel, A. F. (2015). Ten Years of Biosimilars in Europe. Retrieved from http://www.biologicsblog.com/blog/ten-years-of-biosimilars-in-europe/

Jha, D., Mishra, R. K., & Pandey, R. (2013). Biosimilars: Current regulatory perspective and challenges. Journal of pharmacy & bioallied sciences, 5(1), 80-81. doi:10.4103/0975-7406.106569

Joan Rovira, J. E., Leticia García, & Labry, a. A. O. d. (2011). The impact of biosimilars’ entry in the EU market. Andalusian School of Public Health. Retrieved from http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars-market_012011_en.pdf

Jung, S. K., Lee, K. H., Jeon, J. W., Lee, J. W., Kwon, B. O., Kim, Y. J., . . . Chang, S. J. (2014). Physicochemical characterization of Remsima. mAbs, 6(5), 1163-1177. doi:10.4161/mabs.32221

Kay, J. (2011). Biosimilars: A regulatory perspective from America. Arthritis Research and Therapy, 13(3), 112-112. doi:10.1186/ar3310

Fahrul, J. (2015, December 29) Kerjasama LIPI dengan Biofarma.

Antara News. Retrieved from http://www.antaranews.com/foto/94209/kerjasama-lipi-dengan-bio-farma

Lona, O. (2014). Tahun depan pharos jajaki produk implant dan biosimilar. Berita Satu. Retrieved from http://www.beritasatu.com/kesehatan/191718-tahun-depan-phapros-jajaki-produk-implant-dan-biosimilar.html

Mahler, S., & Gray, P. (2011). Biologics and the emergence of biosimilars: innovation driving global opportunity. Journal of Chemical Technology & Biotechnology, 86(7), 893-894. doi:10.1002/jctb.2684

McCamish, M., & Woollett, G. (2011). Worldwide experience with biosimilar development. mAbs, 3(2), 209-217.

Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2013 Tentang Peta Jalan Pengembangan Bahan Baku Obat. (2013)

Prahadi, Y. Y. (2015). 2015, Nilai Pasar Farmasi US$ 6 Miliar. Retrieved from http://swa.co.id/swa/trends/management/2015-nilai-pasar-farmasi-us-6-miliar

Schellekens, H. (2009). Assessing the bioequivalence of biosimilars. Drug Discovery Today, 14(9), 495-499. doi:10.1016/j.drudis.2009.02.003

Schellekens, H., & Moors, E. (2010). Clinical comparability and European biosimilar regulations. Nature biotechnology, 28(1), 28-31. doi:10.1038/nbt0110-28

Sörgel, F., Schwebig, A., Holzmann, J., Prasch, S., Singh, P., & Kinzig, M. (2015). Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics. BioDrugs, 29(2), 123-131. doi:10.1007/s40259-015-0124-7

Wang, J., & Chow, S. C. (2012). On the regulatory approval pathway of biosimilar products. Pharmaceuticals, 5(4), 353-368. doi:10.3390/ph5040353




DOI: http://dx.doi.org/10.14203/ab.v20i2.272

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 ANNALES BOGORIENSES

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Annales Bogorienses Indexed by :

     

  

       

 

 

Statistic Visitors